Anna Eramo, MD

A Collaborative Study to Assess Digitally Enabled Engagement in Major Depressive Disorder (MDD) Within a Large Health System

Objective: Assessment of a digitally enabled care Pathway mobile app designed to improve patient-provider engagement in patients with MDD. A patient interface was used to assess treatment...

Christopher Blair , MS;

Maggie McCue , MS, RD;

Ben Fehnert , MA;

Francesca Cormack , PhD;

Sara Sarkey , PhD;

Anna Eramo , MD;

Ellen Rhodes ;

Christopher Kabir , MS;

Rasha Khatib , MHS;

David Kemp ;

11/22/2019

Personalized Goal Attainment After a Switch to Vortioxetine in Adults With Major Depressive Disorder (MDD): Results of a Phase 4 Open-Label Clinical Trial

This Phase 4 open-label trial evaluated real-world effectiveness of the antidepressant vortioxetine on the ability of patients with MDD to achieve pre-identified treatment goals.

Anna Eramo , MD;

Sagar Parikh , MD;

Lisa Mucha , PhD;

Clement Francois , PhD;

Sara Sarkey , PhD;

03/01/2019

Validation of Goal Attainment Scaling for Depression: Initial Findings From an Open-label Study in Patients Switching to Vortioxetine

Goal attainment scaling (GAS) for evaluating individualized patient treatment goals and progress was adapted for MDD (GAS-D) in an open-label study in patients switching to vortioxetine (...

Maggie McCue , MS, RD;

Lambros Chrones , MD;

Anna Eramo , MD;

Mark Opler , PhD, MPH;

Andrea Norcini Pala , PhD;

Sagar Parikh , MD;

David Hellerstein , MD;

03/01/2019